Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease

Mehta, 2009, Natural course of Fabry disease: changing pattern of causes of death in FOS: Fabry Outcome Survey, J Med Genet, 46, 548, 10.1136/jmg.2008.065904 Yogasundaram, 2017, Clinical features, diagnosis, and management of patients with Anderson-Fabry cardiomyopathy, Can J Cardiol, 33, 883, 10.1016/j.cjca.2017.04.015 Weidemann, 2010, Cardiac challenges in patients with Fabry disease, Int J Cardiol, 141, 3, 10.1016/j.ijcard.2009.08.002 Linhart, 2000, New insights in cardiac structural changes in patients with Fabry's disease, Am Heart J, 139, 1101, 10.1067/mhj.2000.105105 Wu, 2010, Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity, Eur Heart J, 31, 1088, 10.1093/eurheartj/ehp588 Goldman, 1986, Echocardiographic abnormalities and disease severity in Fabry's disease, J Am Coll Cardiol, 7, 1157, 10.1016/S0735-1097(86)80238-8 El Dib, 2016, Enzyme replacement therapy for Anderson-Fabry disease, Cochrane Database Syst Rev, 7 Anderson, 2014, Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study, J Inherit Metab Dis, 37, 969, 10.1007/s10545-014-9717-4 Beck, 2015, Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis, Mol Genet Metab Rep, 3, 21, 10.1016/j.ymgmr.2015.02.002 Kampmann, 2008, Onset and progression of the Anderson-Fabry disease-related cardiomyopathy, Int J Cardiol, 130, 367, 10.1016/j.ijcard.2008.03.007 Germain, 2013, Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry, Genet Med, 15, 958, 10.1038/gim.2013.53 Patel, 2015, Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease, Heart, 101, 961, 10.1136/heartjnl-2014-306782 Seo, 2015, Discrepancies in left ventricular mass calculation based on echocardiography and cardiovascular magnetic resonance measurements in patients with left ventricular hypertrophy, J Am Soc Echocardiogr, 28, 1194, 10.1016/j.echo.2015.06.009 Rombach, 2014, Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis, effectiveness of ERT in different disease stages, J Inherit Metab Dis, 37, 341, 10.1007/s10545-014-9677-8 Stewart, 1999, Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging, Kidney Int, 56, 2248, 10.1046/j.1523-1755.1999.00786.x Missouris, 1996, Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension, J Hypertens, 14, 1005, 10.1097/00004872-199608000-00011 Sirrs, 2014, Outcomes of patients treated through the Canadian Fabry disease initiative, Mol Genet Metab, 111, 499, 10.1016/j.ymgme.2014.01.014 Lang, 2005, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005 Devereux, 1977, Echocardiographic determination of left ventricular mass in man: anatomic validation of the method, Circulation, 55, 613, 10.1161/01.CIR.55.4.613 Mosteller, 1987, Simplified calculation of body-surface area, N Engl J Med, 317, 1098, 10.1056/NEJM198710223171717 Lang, 2015, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 28, 1, 10.1016/j.echo.2014.10.003 Kozor, 2015, A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease, J Cardiovasc Magn Reson, 17, 22, 10.1186/s12968-015-0114-4 Cheng-Baron, 2015, Quantification of circumferential, longitudinal, and radial global fractional shortening using steady-state free precession cines: a comparison with tissue-tracking strain and application in Fabry disease, Magn Reson Med, 73, 586, 10.1002/mrm.25166 Altman, 1999, xii, 611 Liang, 1986, Longitudinal data analysis using generalized linear models, Biometrika, 73, 13, 10.1093/biomet/73.1.13 Nunnally, 1978, xv, 701 Chen, 2016, Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy, Can J Cardiol, 32, 1221.e1, 10.1016/j.cjca.2015.10.033 Weidemann, 2005, The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease, Eur Heart J, 26, 1221, 10.1093/eurheartj/ehi143 Mehta, 2010, Fabry disease: a review of current management strategies, QJM, 103, 641, 10.1093/qjmed/hcq117 Eng, 2006, Fabry disease: guidelines for the evaluation and management of multi-organ system involvement, Genet Med, 8, 539, 10.1097/01.gim.0000237866.70357.c6 Sirrs, 2010, Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative, Mol Genet Metab, 99, 367, 10.1016/j.ymgme.2009.11.001 de Simone, 1998, Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass, J Hypertens, 16, 1207, 10.1097/00004872-199816080-00015 Armstrong, 2012, LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice, JACC Cardiovasc Imaging, 5, 837, 10.1016/j.jcmg.2012.06.003 Mor-Avi, 2004, Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging, Circulation, 110, 1814, 10.1161/01.CIR.0000142670.65971.5F Sirrs SB, Daniel G, Iwanochko R, et al. Canadian Fabry Disease Treatment Guidelines. 2016. Available at: http://www.garrod.ca/wp-content/uploads/Canadian-FD-Treatment-Guidelines-2017.pdf. Accessed May 31, 2018. Sado, 2013, Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping, Circ Cardiovasc Imaging, 6, 392, 10.1161/CIRCIMAGING.112.000070 Thompson, 2013, T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex, Circ Cardiovasc Imaging, 6, 637, 10.1161/CIRCIMAGING.113.000482 Yano, 2016, Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy, Int J Cardiol, 203, 136, 10.1016/j.ijcard.2015.10.140 Moon, 2006, The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease, J Cardiovasc Magn Reson, 8, 479, 10.1080/10976640600605002